Literature DB >> 29687175

Age-specific ALS incidence: a dose-response meta-analysis.

Benoît Marin1,2,3,4,5,6, Andrea Fontana7, Simona Arcuti7,8, Massimilano Copetti7, Farid Boumédiene1,2,3, Philippe Couratier1,2,9, Ettore Beghi4, Pierre Marie Preux1,2,3, Giancarlo Logroscino10,11.   

Abstract

To evaluate the association between worldwide ALS incidence rates and age, using a dose-response meta-analysis. We reviewed Medline and Embase up to July 2016 and included all population-based studies of newly-diagnosed cases, using multiple sources for case ascertainment. A dose-response meta-analysis was performed. A meta-regression investigated potential sources of heterogeneity. Of 3254 articles identified in the literature, we included 41 incidence studies covering 42 geographical areas. Overall, the fit between observed and predicted age-specific rates was very good. The expected variation of ALS incidence with age was characterized, in each study, by a progressive increase in the incidence from the 40s leading to a peak in the 60s or 70s, followed by a sharp decrease. Cochran's Q test suggested a significant heterogeneity between studies. Overall, estimated patterns of ALS age-specific incidence (at which the peak was reached) were similar among subcontinents of Europe and North America: peak of ALS incidence ranged in these areas between 6.98 and 8.17/100,000 PYFU, which referred to age in the range 71.6-77.4 years. The relationship between age and ALS incidence appeared different for Eastern Asia which was characterized by a peak of ALS incidence at 2.20/100,000 PYFU around 75 years of age. This study confirms the consistency of the age-specific ALS incidence pattern within different subcontinents. Age-specific incidence appears lower in Eastern Asia as compared to Europe and North America.

Keywords:  Age-specific; Amyotrophic lateral sclerosis; Epidemiology; Ethnic groups; Incidence

Mesh:

Year:  2018        PMID: 29687175     DOI: 10.1007/s10654-018-0392-x

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  63 in total

Review 1.  Ethnic variation in the incidence of ALS: a systematic review.

Authors:  Simon Cronin; Orla Hardiman; Bryan J Traynor
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

2.  Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study.

Authors:  M Murphy; S Quinn; J Young; P Parkin; B Taylor
Journal:  Neurology       Date:  2008-12-02       Impact factor: 9.910

3.  The epidemiology of motor neurone disease in two counties in the southwest of England.

Authors:  Ibrahim Imam; Susan Ball; Dave Wright; C Oliver Hanemann; John Zajicek
Journal:  J Neurol       Date:  2010-01-22       Impact factor: 4.849

4.  Epidemiologic study of amyotrophic lateral sclerosis in Hawaii. Identification of high incidence among Filipino men.

Authors:  N Matsumoto; R M Worth; L T Kurland; H Okazaki
Journal:  Neurology       Date:  1972-09       Impact factor: 9.910

5.  Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995-2009.

Authors:  Maura Pugliatti; Leslie D Parish; Paola Cossu; Stefania Leoni; Anna Ticca; M Valeria Saddi; Enzo Ortu; Sebastiano Traccis; Giuseppe Borghero; Roberta Puddu; Adriano Chiò; Pietro Pirina
Journal:  J Neurol       Date:  2012-09-30       Impact factor: 4.849

6.  Population-based epidemiology of amyotrophic lateral sclerosis (ALS) in an ageing Europe--the French register of ALS in Limousin (FRALim register).

Authors:  B Marin; B Hamidou; P Couratier; M Nicol; A Delzor; M Raymondeau; M Druet-Cabanac; G Lautrette; F Boumediene; P M Preux
Journal:  Eur J Neurol       Date:  2014-06-09       Impact factor: 6.089

7.  Clinical epidemiology of ALS in Liguria, Italy.

Authors:  Monica Bandettini di Poggio; Maria Pia Sormani; Romina Truffelli; Paola Mandich; Paola Origone; Simonetta Verdiani; Vittorio Mantero; Carlo Scialò; Angelo Schenone; Giovanni Luigi Mancardi; Claudia Caponnetto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2012-10-03       Impact factor: 4.092

8.  Prognosis of amyotrophic lateral sclerosis and the effect of referral selection.

Authors:  J R Lee; J F Annegers; S H Appel
Journal:  J Neurol Sci       Date:  1995-10       Impact factor: 3.181

Review 9.  Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis.

Authors:  Andrea Fontana; Sara Spadaro; Massimiliano Copetti; Belinda Spoto; Lucia Salvemini; Patrizia Pizzini; Lucia Frittitta; Francesca Mallamaci; Fabio Pellegrini; Vincenzo Trischitta; Claudia Menzaghi
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 10.  Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.

Authors:  Benoît Marin; Farid Boumédiene; Giancarlo Logroscino; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Massimilano Copetti; Pierre-Marie Preux; Ettore Beghi
Journal:  Int J Epidemiol       Date:  2017-02-01       Impact factor: 7.196

View more
  12 in total

1.  Changing epidemiology of motor neurone disease in Scotland.

Authors:  Danielle J Leighton; Judith Newton; Laura J Stephenson; Shuna Colville; Richard Davenport; George Gorrie; Ian Morrison; Robert Swingler; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2019-02-25       Impact factor: 4.849

2.  Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a dose-response meta-analysis.

Authors:  Andrea Fontana; Benoit Marin; Jaime Luna; Ettore Beghi; Giancarlo Logroscino; Farid Boumédiene; Pierre-Marie Preux; Philippe Couratier; Massimilano Copetti
Journal:  J Neurol       Date:  2021-02-25       Impact factor: 4.849

3.  Use of Pharyngeal High-Resolution Manometry to Evaluate Dysphagia in Adults with Motor Neurone Disease: A Scoping Review.

Authors:  Eva Mary Diver; Julie Regan
Journal:  Dysphagia       Date:  2022-03-02       Impact factor: 3.438

4.  Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet Neurol       Date:  2018-11-05       Impact factor: 44.182

5.  Association Between Premorbid Body Mass Index and Amyotrophic Lateral Sclerosis: Causal Inference Through Genetic Approaches.

Authors:  Ping Zeng; Xinghao Yu; Haibo Xu
Journal:  Front Neurol       Date:  2019-05-24       Impact factor: 4.003

6.  Amyotrophic Lateral Sclerosis, a Possible Sequela of Chronic Myeloid Leukemia.

Authors:  Irsa Munir; Talha Mehmood; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2019-07-31

7.  Objectives, design and main findings until 2020 from the Rotterdam Study.

Authors:  M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman
Journal:  Eur J Epidemiol       Date:  2020-05-04       Impact factor: 8.082

Review 8.  Potential Preventive Strategies for Amyotrophic Lateral Sclerosis.

Authors:  B Kuraszkiewicz; H Goszczyńska; T Podsiadły-Marczykowska; M Piotrkiewicz; P Andersen; M Gromicho; J Grosskreutz; M Kuźma-Kozakiewicz; S Petri; B Stubbendorf; K Szacka; H Uysal; M de Carvalho
Journal:  Front Neurosci       Date:  2020-05-26       Impact factor: 4.677

9.  Prevalence of amyotrophic lateral sclerosis in Latium region, Italy.

Authors:  Maria Puopolo; Ilaria Bacigalupo; Paola Piscopo; Eleonora Lacorte; Alessandra Di Pucchio; Marialaura Santarelli; Maurizio Inghilleri; Antonio Petrucci; Mario Sabatelli; Nicola Vanacore
Journal:  Brain Behav       Date:  2021-10-30       Impact factor: 2.708

10.  A rare CACNA1H variant associated with amyotrophic lateral sclerosis causes complete loss of Cav3.2 T-type channel activity.

Authors:  Robin N Stringer; Bohumila Jurkovicova-Tarabova; Sun Huang; Omid Haji-Ghassemi; Romane Idoux; Anna Liashenko; Ivana A Souza; Yuriy Rzhepetskyy; Lubica Lacinova; Filip Van Petegem; Gerald W Zamponi; Roger Pamphlett; Norbert Weiss
Journal:  Mol Brain       Date:  2020-03-06       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.